Enzon Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 0.226 million compared to USD 0.407 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. For the nine months, revenue was USD 0.672 million compared to USD 0.018 million a year ago. Net loss was USD 0.234 million compared to USD 0.885 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago.